Cardiovascular Disease

Cardiovascular disease is the leading cause of death in the United States and the single largest driver of healthcare spending — and within cardiovascular disease, heart failure is the condition that most reliably converts independent older adults into long-term care recipients. CVD does not just kill people. It slowly takes their independence, one symptom and one hospitalization at a time. In 2026, approximately 130.6 million American adults — nearly half the adult population — have some form of cardiovascular disease. Heart failure alone affects 6.7 million Americans and is projected to reach 8.7 million by 2030. Atrial fibrillation affects more than 10.5 million Americans and is the leading cause of preventable stroke. One million heart failure hospitalizations occur each year in the United States, and 25% of patients are readmitted within 30 days. Cardiovascular disease is uniquely consequential for long-term care planning because its trajectory is so predictable. The natural history is: silent disease for decades → first event (MI, stroke, AFib, HF hospitalization) → recovery with new medications → progressive symptoms despite optimal therapy → escalating hospitalizations → device or transplant evaluation → dependency. The window for LTC planning is wide — but it closes once symptoms become functional, once an ICD is implanted, or once the first heart failure admission appears in the medical record.

This white paper is written for patients, families, and caregivers facing the cardiovascular journey — from the first elevated blood pressure reading through advanced heart failure and the expensive years of dependency. It covers:

• How heart failure, coronary artery disease, atrial fibrillation, and valvular disease each produce distinct dependency pathways
• The 'four pillars' of guideline-directed medical therapy (GDMT) — ARNI, beta-blockers, MRAs, and SGLT2 inhibitors — and how the Medicare Part D $2,000 cap transforms access
• FDA-approved late-2024 and 2025 game-changers: acoramidis (Attruby) for ATTR cardiac amyloidosis; the TriClip transcatheter tricuspid system; pulsed field ablation for AFib; vutrisiran (Amvuttra) for ATTR-CM
• The 2026 pipeline: CRISPR for transthyretin amyloidosis (a one-time gene edit), aficamten for hypertrophic cardiomyopathy, Lp(a)-lowering drugs, factor XI inhibitors, and AI ECG screening
• Why heart failure hospitalization is the inflection point: 35.7% one-year readmission, 53% fall rate within six months, and the deconditioning cascade that follows
• The LTC underwriting reality — what 'controlled hypertension' versus 'NYHA Class III heart failure' means at the application stage

Cardiovascular disease is not one condition but a family of overlapping disorders of the heart and blood vessels. For long-term care planning, the differences among them matter enormously.

Heart Failure: The Central Player

Heart failure is a clinical syndrome in which the heart cannot pump or fill with enough blood to meet the body's needs. It is not a single disease but the common endpoint of many cardiac conditions — coronary artery disease, hypertension, valvular disease, cardiomyopathy, and others. Modern classification depends on left ventricular ejection fraction (EF), the percentage of blood the left ventricle squeezes out with each beat:

• HFrEF — Heart Failure with reduced Ejection Fraction (EF ≤ 40%)
• HFmrEF — Heart Failure with mildly reduced Ejection Fraction (EF 41–49%)
• HFpEF — Heart Failure with preserved Ejection Fraction (EF ≥ 50%)
• HFimpEF — Heart Failure with improved Ejection Fraction (previously reduced, now > 40%)

HFpEF now accounts for roughly half of all heart failure cases and is rising fastest, driven by aging, obesity, hypertension, and diabetes. HFrEF is more responsive to guideline-directed medical therapy; HFpEF has historically been harder to treat, though SGLT2 inhibitors have changed that picture meaningfully since 2022.

NYHA Functional Class

The New York Heart Association functional classification is the most clinically useful way to think about heart failure severity from a dependency perspective:

ACC/AHA Stages A–D

The American College of Cardiology and American Heart Association stages emphasize the progression of disease and the opportunity for prevention:

• Stage A — At Risk (hypertension, diabetes, obesity, family history) but no structural disease and no symptoms
• Stage B — Structural heart disease (low EF, prior MI, valvular disease) but no symptoms
• Stage C — Structural heart disease with current or prior symptoms of heart failure
• Stage D — Refractory heart failure requiring specialized interventions (LVAD, transplant, hospice)

Coronary Artery Disease and Myocardial Infarction

Coronary artery disease (CAD) — the build-up of cholesterol plaque in the arteries supplying the heart — affects approximately 20 million American adults. Acute myocardial infarction (heart attack) occurs in roughly 805,000 Americans per year; about 200,000 are recurrent events. Survivors live with ischemic cardiomyopathy, which is the most common pathway to HFrEF in the United States.

Atrial Fibrillation

AFib is the most common sustained cardiac arrhythmia, affecting 10.5 million or more Americans and projected to reach 12.1 million by 2030. AFib causes 5x increased stroke risk if untreated, contributes to heart failure, and frequently coexists with the other CVD conditions. The treatment revolution — DOACs replacing warfarin, pulsed field ablation replacing thermal ablation — has transformed AFib care over the past five years.

Valvular Heart Disease

Aortic stenosis (narrowing of the aortic valve) affects 3–5% of adults aged 75 and older and is the most common valve lesion requiring intervention. Mitral regurgitation, tricuspid regurgitation, and other valve diseases together represent a major and rising portion of cardiology workload. Transcatheter valve therapies — TAVR for aortic stenosis (now approximately 45% of all aortic replacements), TEER (MitraClip) for mitral regurgitation, and the FDA-approved-April-2024 TriClip for tricuspid regurgitation — have made valve replacement accessible to older and frailer patients who would never have survived open-heart surgery.

Cardiac Amyloidosis

Long thought to be rare, transthyretin (ATTR) cardiac amyloidosis is now recognized as a substantial cause of heart failure in older adults — autopsy series find amyloid deposits in 25% of hearts in patients aged 80 and older. ATTR-CM is the form for which tafamidis (Vyndaqel/Vyndamax), acoramidis (Attruby, FDA approved November 2024), and vutrisiran (Amvuttra, March 2025) provide disease-modifying treatment. AL amyloidosis is a separate, more aggressive disease caused by an underlying plasma cell disorder, treated by hematology.

Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy (HCM) is a genetic disease affecting approximately 1 in 500 people. Obstructive HCM is now treatable with mavacamten (Camzyos), the first cardiac myosin inhibitor — a major advance over decades of symptomatic-only therapy.

The Florida Context

Florida recorded approximately 50,008 heart disease deaths in 2024, the leading cause of death in the state. Florida's older demographic — particularly in retirement-heavy Southwest Florida — concentrates CVD burden. AFib, aortic stenosis, and HFpEF prevalence are all substantially higher than national averages in age-75+ populations. For LTC advisors working in retiree communities, cardiovascular history must be the lead question in every client conversation.

This section is the clinical heart of why cardiovascular disease matters for long-term care planning. Each condition produces predictable functional consequences. Taken together, they explain why CVD is the most underestimated driver of dependency in modern medicine.

3.1 Heart Failure Hospitalization — The Inflection Point

Heart failure hospitalization is the single most important event in the dependency trajectory of CVD patients. Approximately 1 million HF hospitalizations occur in the United States each year, and the 30- day all-cause readmission rate is 13–25%. One-year readmission reaches 35.7%. The mechanism of decline is the deconditioning cascade:

• Acute decompensation → hospital admission, often 5–7 days
• Bed rest and inactivity → muscle loss (3–5% per week in older patients)
• Discharge → home or SNF with reduced exercise capacity
• Failure to recover prior conditioning → reduced ADL capacity
• Next decompensation → repeat cycle, lower starting point each time

3.2 Atrial Fibrillation and the Stroke Cascade

Untreated AFib produces stroke at five times the rate of patients in sinus rhythm. Stroke is the single most expensive event in the cardiovascular pathway — not in dollars at the time of admission, but in the lifetime cost of post-stroke dependency. Patients with AFib-related strokes are disproportionately disabled because the embolic clots tend to be large and to occlude major arteries.

3.3 Cardiac Cachexia and Sarcopenia

Chronic heart failure produces cardiac cachexia — involuntary weight loss, particularly muscle wasting — in 5–15% of patients, rising to 30%+ in advanced disease. Combined with age-related sarcopenia (muscle loss with aging), this produces severe deconditioning that limits every ADL. The patient who weighs 130 pounds at 5'10" with HFrEF and edema is often hiding a body composition with 70+ pounds of fat-free mass loss.

3.4 Dyspnea and the Limits of ADLs

Shortness of breath is the cardinal symptom of heart failure. Its functional impact escalates step by step:

• Stage 1 (NYHA II) — dyspnea on stairs, hills, brisk walking
• Stage 2 (NYHA III) — dyspnea on level walking, bathing, dressing
• Stage 3 (NYHA III/IV) — dyspnea at rest with any activity (lifting arms, standing)
• Stage 4 (NYHA IV) — orthopnea (cannot lie flat), paroxysmal nocturnal dyspnea, dyspnea at rest

Bathing, in particular, is a high-effort ADL — the combination of warm water (vasodilation), arm elevation (cardiac load), and physical exertion frequently exceeds NYHA III HF patients' tolerance. Many HF patients secretly stop bathing because it triggers severe dyspnea — a hidden hygiene crisis the family eventually notices.

3.5 Cognitive Impairment — 'Cardiogenic Dementia'

Heart failure increases dementia risk by approximately 60%. Cognitive impairment is present in 29% of HF patients overall and in higher percentages of patients with NYHA III–IV disease. Mechanisms include chronically reduced cerebral perfusion, microemboli (particularly from AFib), and the cumulative effect of multiple hospitalizations with delirium episodes.

3.6 Falls — Orthostasis, Syncope, and Deconditioning

CVD patients fall at 2–3x the rate of age-matched controls without CVD. Causes include:

• Orthostatic hypotension from diuretics, ARNI, ACEi/ARB, and beta-blockers
• Bradycardia from beta-blockers, AV node disease, or sick sinus syndrome
• Cardiac syncope (aortic stenosis, ventricular arrhythmia, vasovagal)
• Deconditioning and muscle loss
• Cognitive impairment with impaired hazard recognition

The fall, in turn, frequently produces a hip fracture, an ED visit, a hospitalization, and another step down the dependency ladder. See our companion Falls and Fractures white paper for the full cascade.

3.7 Cardiorenal Syndrome

The heart and kidneys are coupled organs — disease in one accelerates disease in the other. Approximately 50% of heart failure patients have concurrent chronic kidney disease (CKD); approximately 50% of CKD patients have CVD. Diuretic management in cardiorenal syndrome is one of the most challenging problems in clinical medicine, and worsening renal function during HF hospitalization is a strong predictor of mortality and rehospitalization.

3.8 Polypharmacy

The typical advanced HF patient takes 8–12 medications daily, with approximately 50% of HF patients on 10 or more drugs. Polypharmacy in older adults is independently associated with falls, hospitalization, cognitive impairment, and adverse drug events. Managing a 12-medication regimen requires intact cognition, manual dexterity, and engaged family support — all of which CVD itself can erode.

3.9 Implanted Cardiac Devices

Pacemakers (200,000+ implants per year in the U.S.), implantable cardioverter-defibrillators (ICDs, approximately 150,000 per year), cardiac resynchronization therapy (CRT), and Watchman left atrial appendage occlusion devices are increasingly common. These devices extend life and reduce hospitalization but bring their own complications — lead malfunction, infection (1–2% of new implants), inappropriate shocks, generator replacement every 5–10 years, and end-of-life device deactivation conversations.

3.10 LVAD — Mechanical Circulatory Support

Left ventricular assist devices (HeartMate 3) extend life in end-stage HF as either a bridge to transplant or as destination therapy in patients ineligible for transplant. LVAD life expectancy now exceeds five years in many recipients. But LVAD living is a 24-hour caregiving project — driveline care, battery management, anticoagulation, infection vigilance, and constant readiness for emergencies. LVAD recipients are not LTC insurance candidates after implant; the question is whether they were insured before.

Cardiovascular diagnosis is part history, part physical exam, part imaging, and part laboratory testing. Getting the diagnosis right — and the staging right — drives treatment selection and prognosis.

Natriuretic Peptides — BNP and NT-proBNP

B-type natriuretic peptide (BNP) and N-terminal pro-BNP (NT-proBNP) are released from stretched ventricular myocardium. They are the single most useful blood tests in suspected heart failure. Elevated levels strongly suggest HF in symptomatic patients; serial measurements help track response to therapy. BNP is also influenced by age, kidney function, obesity (lower in obese patients), and AFib.

Echocardiography

Transthoracic echocardiogram (TTE) is the workhorse cardiac imaging test. It provides EF measurement, structural assessment (chamber sizes, wall thickness, valve function), and many derived hemodynamic estimates. Most HF patients have echos repeated annually or after significant clinical changes. Transesophageal echo (TEE) is reserved for specific questions (LA appendage clot before cardioversion, endocarditis, complex valve assessment).

ECG and Ambulatory Monitoring

The 12-lead electrocardiogram remains the foundational test for arrhythmia, ischemia, conduction disease, and chamber enlargement. Ambulatory monitoring — Holter (24–48 hours), longer-duration patch recorders (Zio, BodyGuardian), and implantable loop recorders (Reveal LINQ, BIOMONITOR) — diagnoses paroxysmal arrhythmia and unexplained syncope. AI-augmented ECG screening (Eko, AliveCor) received FDA clearance for HF and aortic stenosis screening in April 2024, expanding primary-care diagnostic capability.

Cardiac MRI and CT

Cardiac magnetic resonance imaging (CMR) provides the most accurate EF measurement, detects scar (late gadolinium enhancement) and infiltration (amyloid, sarcoid), and is essential for cardiomyopathy workup. Coronary CT angiography has largely replaced diagnostic catheterization for evaluating chest pain in many settings, with high negative predictive value for ruling out obstructive CAD.

Cardiac Catheterization

Left heart catheterization with coronary angiography evaluates CAD and enables PCI. Right heart catheterization measures filling pressures and is essential in advanced HF evaluation, particularly for transplant or LVAD candidacy and for pulmonary hypertension workup.

Specialized Diagnostics for Amyloidosis

Technetium-99m pyrophosphate (Tc-PYP) scintigraphy diagnoses ATTR cardiac amyloidosis non-invasively. A positive scan in a patient with HFpEF and increased wall thickness essentially confirms ATTR-CM and triggers consideration of tafamidis or acoramidis. The diagnostic algorithm has been transformed since 2019; tens of thousands of patients now diagnosed with ATTR-CM were previously labeled as HFpEF of unknown cause.

Cardiovascular pharmacology has transformed three times in the past decade — the introduction of ARNI (sacubitril/valsartan), the SGLT2 inhibitor revolution that expanded into HFpEF in 2022, and the wave of disease-modifying therapies for previously untreatable conditions like ATTR-CM and HCM.

5.1 The 'Four Pillars' of HFrEF GDMT

Modern guideline-directed medical therapy (GDMT) for HFrEF rests on four foundation drug classes. All four should be initiated promptly after diagnosis and uptitrated to maximally tolerated doses within weeks to months — the 'rapid sequential' approach has replaced the older slow approach.

Pillar 1: ARNI (Angiotensin Receptor / Neprilysin Inhibitor)

• Sacubitril/valsartan (Entresto) — replaced ACEi/ARB as first-line in HFrEF
• Reduces HF hospitalization by 21% and cardiovascular death by 20% versus enalapril (PARADIGM-HF)
• List price approximately $7,200/year; Medicare Part D IRA-negotiated price reduces patient cost substantially in 2026

Pillar 2: Evidence-Based Beta-Blockers

• Carvedilol (Coreg) — most commonly used
• Metoprolol succinate (Toprol XL) — extended release
• Bisoprolol — alternative
• Caution: only these three are evidence-based for HFrEF; immediate-release metoprolol and atenolol are not GDMT

Pillar 3: Mineralocorticoid Receptor Antagonist (MRA)

• Spironolactone (Aldactone) — first-line, low cost
• Eplerenone — used when gynecomastia develops with spironolactone
• Finerenone (Kerendia) — newer non-steroidal MRA; FDA approved for HFmrEF/HFpEF in July 2025 (FINEARTS-HF)

Pillar 4: SGLT2 Inhibitor

• Dapagliflozin (Farxiga) — DAPA-HF for HFrEF, DELIVER for HFpEF
• Empagliflozin (Jardiance) — EMPEROR-Reduced for HFrEF, EMPEROR-Preserved for HFpEF
• Now approved for HF across the entire EF spectrum — the only drug class to demonstrate this
• Annual cost approximately $6,000; Medicare Part D $2,000 OOP cap caps annual patient cost

5.2 Other Heart Failure Medications

• Vericiguat (Verquvo) — soluble guanylate cyclase stimulator; for HFrEF with recent worsening
• Ivabradine (Corlanor) — for HFrEF with elevated resting heart rate despite maximally tolerated beta-blocker
• Loop diuretics — furosemide, torsemide, bumetanide; mainstay of volume management
• Hydralazine + isosorbide dinitrate — particularly effective in self-identified Black HF patients (A- HeFT)
• Digoxin — limited role; reduces hospitalization, not mortality

5.3 Coronary Artery Disease Medications

• High-intensity statins — atorvastatin 40–80 mg, rosuvastatin 20–40 mg; foundational for secondary prevention
• Ezetimibe — add-on for LDL not at goal on statins
• PCSK9 inhibitors — alirocumab (Praluent), evolocumab (Repatha); injectable, every 2 weeks
• Inclisiran (Leqvio) — small interfering RNA, twice yearly subcutaneous
• Bempedoic acid (Nexletol) — oral, for statin-intolerant patients
• Antiplatelets — aspirin 81 mg for secondary prevention; clopidogrel, ticagrelor, prasugrel post- PCI

5.4 Atrial Fibrillation Medications

• Apixaban (Eliquis) — most prescribed DOAC; twice daily
• Rivaroxaban (Xarelto) — once daily
• Dabigatran (Pradaxa)
• Edoxaban (Savaysa)
• Warfarin remains in use for mechanical valves and select cases; replaced by DOACs for non-valvular AFib
• Rate control — metoprolol, diltiazem, verapamil
• Rhythm control — amiodarone, dofetilide, flecainide, propafenone, dronedarone

5.5 Disease-Modifying Therapy for ATTR Cardiac Amyloidosis

Three FDA-approved therapies now exist for ATTR-CM, a condition that was untreatable a decade ago:

• Tafamidis (Vyndaqel 80 mg / Vyndamax 61 mg) — TTR stabilizer, oral, FDA approved 2019; annual cost approximately $225,000
• Acoramidis (Attruby) — TTR stabilizer, oral, FDA approved November 2024; ATTRibute-CM trial demonstrated mortality and hospitalization benefit
• Vutrisiran (Amvuttra) — RNAi-based TTR silencer; FDA approved for ATTR-CM March 2025; subcutaneous injection every three months

5.6 Hypertrophic Cardiomyopathy

• Mavacamten (Camzyos) — first cardiac myosin inhibitor; FDA approved 2022 for symptomatic obstructive HCM; requires REMS program for risk monitoring
• Aficamten (Cytokinetics) — next-generation cardiac myosin inhibitor; SEQUOIA-HCM positive in 2024; potential 2026 FDA approval

5.7 Obesity-HFpEF and GLP-1 Agonists

Semaglutide (Wegovy/Ozempic) and tirzepatide (Zepbound) — GLP-1 and GLP-1/GIP agonists originally developed for diabetes and weight loss — have now demonstrated clear cardiovascular benefit. The STEP-HFpEF trial showed semaglutide improves symptoms and reduces hospitalization in obese HFpEF patients. Tirzepatide showed similar benefits in SUMMIT (2024). This represents a new category: obesity-HFpEF as a treatable phenotype.

5.8 Cost and Access

CVD medication costs have been a major affordability concern, particularly for the newer disease-modifying agents:

• Entresto, SGLT2 inhibitors, PCSK9 inhibitors, GLP-1 agonists, mavacamten, tafamidis, acoramidis — all carry substantial list prices
• Medicare Part D $2,000 annual out-of-pocket cap (effective 2025 under the Inflation Reduction Act) transforms patient affordability
• Entresto and several other major cardiovascular drugs are subject to Medicare price negotiation under the IRA; 2026 negotiated prices substantially reduce program cost
• Patient assistance programs and copay cards remain important for commercially insured patients

Procedural and device cardiology has been transformed by the catheter-based revolution. Procedures that required open-heart surgery a decade ago are now done with same-day discharge.

6.1 Percutaneous Coronary Intervention (PCI) and CABG

Approximately one million PCI procedures (angioplasty with stenting) are performed annually in the United States. Drug-eluting stents are now standard; bare-metal stents have largely disappeared. Coronary artery bypass grafting (CABG) remains the preferred approach for left main and multivessel disease in many patients, particularly diabetics. CABG volume has declined as PCI capabilities have expanded, but it remains a substantial procedure with predictable post-operative rehabilitation needs.

6.2 Transcatheter Valve Therapy

TAVR — Transcatheter Aortic Valve Replacement

TAVR has been the most transformative cardiac procedure of the past 15 years. From a niche option for inoperable patients in 2011, TAVR now accounts for approximately 45% of all aortic valve replacements in the United States and is expanding into low-risk and younger patient populations. Standard recovery involves 1–3 day hospital stay and 2–4 weeks of light-duty restrictions — a fraction of the SAVR (surgical) recovery.

TEER — Transcatheter Edge-to-Edge Repair

The MitraClip device clips the mitral valve leaflets together, reducing mitral regurgitation in patients who cannot tolerate open surgery. Indications have expanded from primary mitral regurgitation to functional MR in HF (COAPT trial). The TriClip system received FDA approval on April 1, 2024 as the first transcatheter therapy for tricuspid regurgitation — a condition affecting an estimated 1.6 million Americans, most of whom had been untreatable until 2024.

6.3 Cardiac Implantable Electronic Devices

6.4 Catheter Ablation for Atrial Fibrillation

Catheter ablation has become an increasingly first-line strategy for symptomatic AFib, particularly paroxysmal AFib. The major innovation of 2023–2024 is pulsed field ablation (PFA) — a non-thermal energy modality that selectively ablates cardiac tissue while sparing the esophagus, phrenic nerve, and pulmonary veins. The Medtronic Affera mapping and PFA system received FDA approval in October 2024, joining the Boston Scientific FARAPULSE system. PFA is faster than radiofrequency ablation, with comparable or better efficacy and a much-reduced complication profile.

6.5 Mechanical Circulatory Support

LVAD — Left Ventricular Assist Device

The HeartMate 3 (Abbott) is the dominant LVAD in current practice. As destination therapy (not bridge to transplant), LVAD survival now reaches 5 years in over 50% of patients in some series. Implantation costs approximately $148,000+; lifetime care including hospitalizations and disposables exceeds $750,000.

Heart Transplantation

Approximately 3,800 heart transplants are performed annually in the United States — limited by donor availability. One-year survival exceeds 90%; five-year survival approaches 75%. Lifetime cost of heart transplant care exceeds $1.7 million in current dollars.

6.6 Cardiac Rehabilitation

Cardiac rehabilitation — a structured program of supervised exercise, education, and risk-factor management — is one of the most underutilized evidence-based interventions in cardiology. It reduces mortality by 20–25% after MI, CABG, or PCI. Only about 25% of eligible patients enroll. Medicare covers up to 36 sessions for qualifying patients, and home-based cardiac rehab has expanded access since 2020. For LTC purposes, completion of cardiac rehab signals active engagement and is favorable for underwriting.

Cardiology in 2026 has multiple genuinely novel mechanisms in late-stage development.

7.1 CRISPR Gene Editing for ATTR Amyloidosis

7.2 Lp(a)-Lowering Therapies

Lipoprotein(a) — Lp(a) — is a genetically determined atherogenic particle present at elevated levels in approximately 20% of the population. Until now, no targeted therapy has existed to lower Lp(a). Three late-stage candidates in 2026:

• Pelacarsen (Novartis) — antisense oligonucleotide, Phase 3 HORIZON trial reading out 2026
• Olpasiran (Amgen) — small interfering RNA, Phase 3 OCEAN(a)-Outcomes
• Lepodisiran (Lilly) — long-duration siRNA, Phase 3 ACCLAIM-Lp(a)

If any of these demonstrate cardiovascular outcome benefit, it would establish a new disease-modifying category and identify a previously untreatable population at high cardiovascular risk.

7.3 Factor XI Inhibitors — Safer Anticoagulation

Factor XI inhibition offers the promise of anticoagulation without bleeding — based on the observation that congenital Factor XI deficiency causes minimal spontaneous bleeding. Asundexian (Bayer) and milvexian (BMS/Janssen) are in Phase 3 trials. If successful, Factor XI inhibitors would expand anticoagulation to older AFib patients currently denied DOACs because of bleeding risk.

7.4 Aficamten for HCM

Aficamten (Cytokinetics) is a next-generation cardiac myosin inhibitor for obstructive HCM. The SEQUOIA-HCM Phase 3 trial reported positive results in 2024. FDA approval is anticipated in 2026. Aficamten may offer a more favorable PK profile and simpler monitoring compared to mavacamten — expanding access for HCM patients.

7.5 Next-Generation LVADs and Partial Heart Replacement

Smaller, fully implantable, transcutaneous-power LVADs are in early development. Partial heart replacement devices (Realheart, others) attempt to provide pulsatile flow and easier implantation. Heart-in-a-box (BiVACOR) total artificial heart received its first human implants in 2024–2025.

7.6 AI-Augmented Diagnostics

AI-enabled ECG analysis has been one of the most successful AI-in-medicine applications. Mayo Clinic's algorithm identifies reduced EF from a 12-lead ECG with high accuracy. Eko Health received FDA clearance in April 2024 for an AI stethoscope identifying low EF and AFib. AliveCor's KardiaMobile continues to expand consumer-grade ECG diagnostics. These tools democratize cardiology screening — particularly important in primary care and resource-limited settings.

7.7 HFpEF Therapeutics Beyond SGLT2

HFpEF — historically the harder-to-treat half of heart failure — is finally getting attention. SGLT2 inhibitors and finerenone are now established; semaglutide and tirzepatide have demonstrated benefit in obesity-HFpEF; the pipeline includes selective aldosterone modulators, novel anti-inflammatory agents, and metabolic modulators. The next 5 years should see HFpEF treatment options approach the depth of HFrEF GDMT.

Cardiovascular disease is the most expensive disease category in American medicine — and the cost is concentrated in hospitalizations and long-term care, not in office visits or routine medications.

8.1 Aggregate U.S. Economic Burden

8.2 Procedure and Device Costs

8.3 Medication Costs

Annual costs of major cardiovascular medications at list price (before insurance, rebates, or the Medicare Part D OOP cap):

• Entresto (sacubitril/valsartan) — approximately $7,200/year; IRA-negotiated price effective
• Farxiga or Jardiance (SGLT2i) — approximately $6,000/year
• Repatha or Praluent (PCSK9i) — approximately $5,800/year
• Leqvio (inclisiran) — approximately $6,500/year
• Camzyos (mavacamten) — approximately $85,000/year
• Vyndaqel/Vyndamax (tafamidis) — approximately $225,000/year
• Attruby (acoramidis) — approximately $244,500/year
• Amvuttra (vutrisiran) — approximately $476,000/year

8.4 Long-Term Care Costs — The Real Number

As with every condition in this series, the dollars that families actually feel are LTC dollars:

Source: CareScout (formerly Genworth) 2025 Cost of Care Survey. Florida 2025 LTC figures: SNF private $91,250 (national rank 48 — lower than median), AL $67,200, home health aide $68,640. Florida's lower-than-national LTC costs combined with high CVD burden creates a particular planning context for retirement-community advisors.

Cardiovascular disease is the leading underlying condition in nursing home admissions, and heart failure is the single most common diagnosis in 30-day readmission penalty data. The pathway from independent living to dependency is well characterized.

9.1 ADL Impact by NYHA Class and Symptom

9.2 The HF Readmission Cycle

As noted earlier, one-year readmission for HF reaches 35.7%. Each readmission is, on average, accompanied by a stepwise loss of functional capacity. The cycle proceeds:

• First admission → home recovery, often successful, restored independence
• Second admission → home or short SNF; cardiac rehab considered; activity limited
• Third admission → SNF for post-acute recovery; home help required
• Fourth admission and beyond → palliative care, hospice, or assisted living placement

9.3 Post-MI and Post-Cardiac-Surgery Rehabilitation

After an uncomplicated MI, patients typically need 2–8 weeks of recovery before returning to most activities. CABG recovery extends to 6–12 weeks with sternal precautions (no lifting >5 lb, no pushing/pulling) for 8–12 weeks. Cardiac rehabilitation — 36 sessions over 12 weeks, Medicare-covered — substantially reduces re-event risk and supports functional recovery. The patient who completes cardiac rehab and returns to baseline activity is a different long-term risk profile from the patient who does not.

9.4 Stroke from AFib

AFib without anticoagulation produces strokes that are typically larger and more disabling than non-cardioembolic strokes. A single AFib-related stroke can convert an independent older adult to a nursing-home resident. The companion Stroke/CVA white paper covers post-stroke trajectory in detail.

9.5 LVAD Home Care

LVAD home life is a 24-hour caregiving project. Requirements include:

• Driveline care — sterile dressing changes 2–3 times per week
• Battery management — typically 12–14 hours per charge
• Continuous awareness of pump function — alarms require response
• Anticoagulation management — warfarin INR every 1–2 weeks initially
• Infection vigilance — driveline infections are the most common LVAD complication
• Emergency readiness — VAD alarm response, ER access, pump exchange protocols

LVAD recipients require a designated primary caregiver who has completed the implant center's training program. The caregiver burden is typically 100+ hours per month in the first 6 months post-implant. This is not covered by Medicare beyond home health visits; the family or paid caregivers supply almost all of it.

9.6 Hospice Eligibility in End-Stage HF

Heart failure patients qualify for Medicare hospice when they have:

• NYHA Class IV symptoms despite optimal medical therapy
• EF ≤ 20% (preferred but not required)
• Refractory symptoms, recurrent admissions, or ICD shocks
• Cardiologist agreement that prognosis is ≤ 6 months

Hospice in end-stage HF is dramatically underused. Many patients die in ICUs after multiple admissions when hospice would have offered better symptom control and family support. The conversation about hospice eligibility belongs early in NYHA IV disease — not at the final admission.

Cardiovascular caregiving is among the most time-intensive and emotionally demanding forms of family caregiving — particularly for heart failure, where daily decisions about medications, weight, fluid, and symptoms shape outcomes.

10.1 Time Demands

• Medication management — typically 8–12 medications daily, often with different schedules
• Symptom monitoring — daily weights, edema check, dyspnea assessment, BP and HR
• Fluid and sodium restriction — meal planning, label reading, intake tracking
• Appointments — cardiology every 1–3 months, primary care, lab visits, device checks, cardiac rehab 3x/week initially
• Hospital and ED visits — average 1–2 per year in advanced HF

10.2 Medication Management Complexity

A typical NYHA III HF patient on optimal GDMT plus comorbidity treatments takes:

• ARNI (Entresto) — twice daily
• Beta-blocker (carvedilol) — twice daily
• MRA (spironolactone) — once daily
• SGLT2 inhibitor (Jardiance) — once daily
• Loop diuretic (furosemide or torsemide) — once or twice daily, often with PRN escalation
• Potassium supplement — once daily
• DOAC (Eliquis) — twice daily, if AFib
• High-intensity statin — once daily
• Aspirin — once daily
• Plus diabetes meds, BPH meds, antidepressants, sleep aids as comorbidities require

Twelve medications, three different times of day, with weight-based PRN diuretic escalation. Most older patients cannot manage this alone — and medication non-adherence is the leading cause of HF rehospitalization.

10.3 Recognition of Decompensation

Caregivers become front-line clinical observers. They learn to recognize:

• Weight gain of 2 lb in 24 hours or 5 lb in a week — alert to clinic
• Increasing edema in legs, abdomen, scrotum
• Orthopnea — needing more pillows to sleep
• Decreasing exercise tolerance — fewer minutes of walking, more chair time
• New or worsening confusion — often the earliest sign of low output

Early recognition of decompensation, paired with telephone access to the HF clinic, can prevent hospitalizations. But this requires a knowledgeable, present caregiver.

10.4 Emotional Burden

Heart failure caregivers report depression and anxiety rates substantially above the general population. The combination of:

• Constant vigilance
• Progressive decline despite best efforts
• Hospitalizations and near-death experiences
• Difficult conversations about advance directives, DNR, ICD deactivation
• Anticipatory grief

These exact a heavy emotional toll. Caregiver support programs, respite care, and palliative care involvement substantially help — but most families do not access them until the final months.

10.5 Financial Burden

Beyond direct out-of-pocket medical costs, families incur:

• Lost income from caregiver work reduction
• Home modifications (chair lifts, grab bars, walk-in tubs, ramps)
• Equipment (scales, BP cuffs, oxygen concentrators)
• Paid caregivers when family caregivers cannot cover all hours
• Transportation costs — especially in non-urban settings

Estimated U.S. value of informal cardiovascular caregiving exceeds $3 billion annually — and this number is widely considered to understate the true economic contribution.

Cardiovascular disease underwriting in long-term care insurance is highly nuanced. Two patients with the same diagnosis can receive opposite decisions depending on EF, NYHA class, recent events, device status, and stability.

11.1 The Key Underwriting Questions

• Which cardiovascular conditions are diagnosed (HTN, CAD, MI, HF, AFib, valvular, cardiomyopathy)?
• When was the most recent cardiovascular event (MI, hospitalization, intervention)?
• Current EF and NYHA class for HF patients
• Current medications and doses, particularly diuretic dose
• Implanted devices — pacemaker, ICD, CRT, LVAD, Watchman
• Procedure history — PCI, CABG, TAVR, MitraClip, ablation
• Functional capacity — METs, exercise tolerance, ADL limitations
• Recent echo, ECG, stress test results
• Any cognitive impairment from cardiogenic causes
• Smoking history and current status

11.2 Decision Framework by Scenario

11.3 Hybrid and Alternative Options

For borderline cardiovascular profiles or clients past the traditional LTCI window:

• Hybrid life/LTC policies — often more flexible underwriting than standalone LTCI
• Annuity-linked LTC riders — some accept lower health standards
• Accelerated death benefit riders in existing life insurance — may cover some LTC costs
• Critical illness insurance — covers heart attack, stroke, and CABG as named conditions

11.4 The 'Stable on Optimized GDMT' Planning Window

The most important message for cardiovascular patients considering LTC planning: do not wait until you have a heart failure hospitalization in the medical record. The decade between elevated blood pressure or first arrhythmia (ages 50–65) and significant functional limitation (ages 65–80) is the planning window. During this window, most CVD patients are still insurable at standard or individual-consideration rates. Once any of the following occur, the window typically closes:

• First heart failure hospitalization
• NYHA Class III symptoms documented
• ICD implantation
• LVAD evaluation
• Recent CV event within 12 months
• Multiple comorbidities (CVD + diabetes + CKD + cognitive impairment)

12.1 For Individuals and Families

Message 1: Prevention works — and the window starts at 40, not 60. Aggressive management of hypertension, diabetes, dyslipidemia, and obesity in midlife produces dramatically lower cardiovascular event rates over the following decades. The 50-year-old with blood pressure 145/90 'borderline,' LDL 145, and BMI 31 is not 'low risk' — that patient is on a 20-year trajectory toward CAD, heart failure, and dependency. Cardiovascular prevention is one of the highest-yield interventions in medicine.

Message 2: GDMT adherence is dependency prevention. Patients on all four pillars of HFrEF GDMT — ARNI, beta-blocker, MRA, SGLT2 inhibitor — at maximally tolerated doses have approximately 73% lower mortality risk than patients on conventional therapy. Yet only about 25% of eligible patients are on all four. Asking the cardiologist 'am I on all four pillars?' is one of the highest-value questions in modern medicine.

Message 3: Weight, sodium, fluid — every day. Daily morning weight on the same scale. Same time. After voiding. Recorded. Sodium restriction (target 2,000–2,300 mg/day). Fluid restriction when prescribed. These are not lifestyle suggestions — they are clinical interventions that prevent hospitalization. Most heart failure decompensations are predicted by 2–3 days of weight gain that no one noticed.

Message 4: Cardiac rehab — go. After MI, CABG, PCI, valve surgery, or new HF diagnosis, Medicare covers 36 cardiac rehabilitation sessions. Cardiac rehab reduces mortality 20–25% and improves quality of life. Yet only 25% of eligible patients enroll. If your cardiologist did not refer you, ask.

Message 5: Advance directives and palliative care — early. Heart failure is a terminal illness for many patients, with median survival of 5 years after diagnosis. Advance directives should be in place by NYHA II, not waiting for NYHA IV. Palliative care consultation in advanced HF reduces hospitalizations, improves symptom control, and supports family decision-making. ICD deactivation conversations are part of end-of-life care planning.

Message 6: LTC planning belongs in your 50s, not your 70s. The cardiovascular journey from elevated blood pressure to NYHA III heart failure typically spans 20–30 years. The planning window for LTC insurance is during that decade between first diagnoses (hypertension, CAD, AFib) and functional symptoms (NYHA III). Premiums at 55 are dramatically lower than at 65, and approval rates are dramatically higher. The CVD client who waits until the first hospitalization is the client who finds out the window has closed.

12.2 For LTC Planning Advisors

• Lead with cardiovascular history in every client interview — ask about HTN, MI, stents, AFib, CHF, devices, family history
• Pre-screen with carriers when EF is reduced, NYHA class is II or worse, or there is any device implantation history
• Distinguish between 'stable, well-controlled CAD post-PCI >12 months' and 'recent CV event within 6 months' — they are vastly different underwriting categories
• Use functional language: 'How many flights of stairs can you climb without stopping?' 'Can you walk to the mailbox?' 'Do you sleep flat or propped up?' These reveal NYHA class better than the chart
• Florida and Southeast agents: high cardiovascular burden in older population means start the conversation earlier — at age 50, not at age 65
• The 'all four pillars' patient with stable HFrEF and no ADL limit may be insurable on individual consideration — do not auto-decline; pre-screen with specific carriers

12.3 Key Resources

• American Heart Association — heart.org — patient education, statistics, advocacy
• American College of Cardiology — acc.org — clinical guidelines, CardioSmart for patients
• Heart Failure Society of America — hfsa.org — HF-specific clinical and patient resources
• HeartFailureMatters.org — patient-focused HF education
• CDC Heart Disease Program — cdc.gov/heartdisease — prevalence data, prevention resources
• NIH NHLBI — nhlbi.nih.gov — research and patient education
• Mended Hearts — mendedhearts.org — peer support for heart patients
• WomenHeart — womenheart.org — women's heart disease education and advocacy
• ClinicalTrials.gov — current enrolling trials for CRISPR ATTR, Lp(a), aficamten, factor XI
• CareScout Cost of Care — carescout.com/cost-of-care — national and state LTC cost data